Stay updated on Pembrolizumab vs BCG in High-Risk NMIBC & NMI-UTUC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab vs BCG in High-Risk NMIBC & NMI-UTUC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab vs BCG in High-Risk NMIBC & NMI-UTUC Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been pushed back from June 2025 to July 2025.
    Difference
    0.8%
    Check dated 2025-06-19T20:01:23.000Z thumbnail image
  3. Check
    21 days ago
    No Change Detected
  4. Check
    28 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T11:20:51.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    2%
    Check dated 2025-05-29T06:04:43.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The page has updated its date references, moving from March 2025 to May 2025, indicating a shift in the timeline of events or information presented.
    Difference
    0.6%
    Check dated 2025-05-22T03:37:55.000Z thumbnail image
  7. Check
    64 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T14:20:50.000Z thumbnail image
  8. Check
    78 days ago
    Change Detected
    Summary
    The webpage has been updated to reflect a new phase II trial of Pembrolizumab (MK-3475) in combination with Bacillus Calmette-Guérin (BCG) for high-risk T1 bladder cancer and high-grade NMI-UTUC, with significant changes in the trial's description and inclusion criteria.
    Difference
    43%
    Check dated 2025-04-16T10:48:18.000Z thumbnail image

Stay in the know with updates to Pembrolizumab vs BCG in High-Risk NMIBC & NMI-UTUC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs BCG in High-Risk NMIBC & NMI-UTUC Clinical Trial page.